Rep. Pete Sessions Claims Marijuana Use 'Makes You a Loser in Life'

Sessions Escalates Anti-Cannabis Rhetoric on Industry Podcast

Rep. Pete Sessions delivered sweeping anti-cannabis claims during a July 10 appearance on 'High Stakes,' a podcast produced by the cannabis industry. The Texas Republican, one of Congress's most vocal opponents of federal legalization, used the platform to assert that marijuana damages users' genetic material and leads to personal failure. He's voted against every cannabis reform measure since returning to Congress in 2021 after a two-year hiatus.

His appearance on an industry-produced podcast is unusual. Sessions has historically declined invitations from cannabis advocacy groups and industry forums. Choosing to engage with 'High Stakes' suggests a deliberate strategy — carrying anti-legalization messaging directly into reform-friendly media channels.

Sessions represents Texas's 17th Congressional District, a central Texas seat covering parts of Waco and College Station. Texas remains one of 12 states with no legal adult-use or comprehensive medical cannabis program.

DNA and 'Loser' Claims Lack Scientific Support

Sessions's assertion that cannabis 'hurts your DNA' doesn't align with current peer-reviewed research on cannabinoid pharmacology. The National Institute on Drug Abuse, the federal agency charged with studying substance abuse, doesn't list genetic damage among documented risks of cannabis use. NIDA's 2025 research summary identifies cognitive impairment in adolescent users and respiratory irritation from smoking as primary concerns. No mention of DNA alteration.

The 'loser in life' characterization? That's a value judgment, not a clinical finding. Longitudinal studies on cannabis use and life outcomes show correlation between heavy adolescent use and lower educational attainment, but researchers consistently note confounding variables including socioeconomic status and co-occurring mental health conditions. No major medical body has endorsed the framing that cannabis use categorically produces 'losers.'

Sessions didn't cite specific studies or data sources during the podcast appearance. His office hasn't responded to requests for clarification on the scientific basis for the DNA claim.

Women 'Taken Advantage Of' Comment Draws Immediate Pushback

Sessions told the podcast that marijuana use leads to young women being 'taken advantage of,' a statement cannabis advocates immediately labeled as victim-blaming. He didn't elaborate on whether he was referring to sexual assault, financial exploitation, or another form of harm. He also didn't specify whether he believes women are uniquely vulnerable to cannabis-related exploitation or whether the comment applies to all users.

The framing shifts responsibility from predators to victims and uses a debunked 'gateway' logic that has no place in 2026 drug policy discourse.

Morgan Fox, a longtime cannabis policy analyst, said the remark echoes discredited 'reefer madness' narratives from the 1930s. Fox noted that modern research on substance use and sexual violence consistently identifies alcohol, not cannabis, as the substance most commonly involved in drug-facilitated assault. A 2024 Department of Justice study found alcohol present in 68 percent of reported sexual assaults involving substances, compared to 11 percent for cannabis.

Sessions's Legislative Record on Cannabis

Sessions has voted against every major cannabis reform bill to reach the House floor since 2021, including the SAFE Banking Act, the MORE Act, and the STATES Act. He co-sponsored H.R. 2891 in the 118th Congress, a bill that would've increased federal penalties for cannabis trafficking near schools. That bill died in committee without a hearing.

Sessions sits on the House Rules Committee, a powerful panel controlling which amendments reach the floor during debate. In that role, he's blocked multiple attempts to attach cannabis banking protections to must-pass appropriations bills. His opposition has been consistent across Democratic and Republican House majorities.

His district includes Texas A&M University, a land-grant institution that's received federal grants to study hemp cultivation and cannabinoid extraction. Sessions hasn't publicly opposed hemp research, which was legalized under the 2018 Farm Bill.

Political Context and 2026 Midterm Implications

Sessions faces no serious primary challenger in Texas's 17th District and is favored to win re-election in November. His seat is rated R+18 by the Cook Political Report. Polling in his district hasn't tested voter attitudes on cannabis policy specifically, but statewide Texas polling from the University of Texas at Austin showed 68 percent support for medical cannabis legalization in March 2026.

His remarks come as federal cannabis policy remains in limbo. The Drug Enforcement Administration's proposed rule to reschedule cannabis from Schedule I to Schedule III is under review at the Office of Management and Budget. If finalized, rescheduling would reduce federal tax burdens on cannabis businesses under Internal Revenue Code Section 280E but wouldn't legalize the plant for recreational use.

For full background on congressional opposition to cannabis reform, see the CannIntel topic hub on Congressional Cannabis Opposition.

Sessions hasn't announced plans to introduce new anti-cannabis legislation this session. His next scheduled public appearance is a town hall in Waco on July 18. Cannabis policy isn't listed on the agenda.